ENGAGE AF-TIMI 48

The purpose of this study was to demonstrate the safety and efficacy profile, in two different dose regimens of DU-176b, (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation. Patients were randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, & Warfarin.

PRESENTATIONS

TIMI 48 Slides
Biomarkers for the Assessment of Stroke-Systemic Embolism and Bleeding Risk in Patients with AF in ENGAGE (Berg AHA 2018)
HF Hospitalization and Mortality in Non-Valvular AF (Inciardi ESC 2019)
Edoxaban versus Warfarin in Atrial Fibrillation Patients with Low, Mid and High Body Weight in ENGAGE (Boriani ESC 2019)
ENGAGE Genetics (Marston AHA 2019)

PUBLICATIONS

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial

Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial

Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial

Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups

Left atrial structure and function and the risk of death or heart failure in atrial fibrillation

Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48

Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis

Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial

Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials

Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48

Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial

The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials

High-Dose Edoxaban Regimen versus Warfarin in Patients With Atrial Fibrillation and Established Coronary Artery Disease: Insights From the ENGAGE AF-TIMI 48 Trial

Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial

Edoxaban Versus Warfarin In Atrial Fibrillation Ablation: First Experience From The ENGAGE AF TIMI 48 Trial

Association Of Genetic Risk Score With Burden Of Atrial Fibrillation: An ENGAGE AF-TIMI 48 Analysis

Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease

Efficacy and safety of edoxaban vs. warfarin in patients with atrial fibrillation and hepatic disease: Insights from the ENGAGE AF-TIMI 48 trial

A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial

Efficacy And Safety Of Edoxaban In Patients With Atrial Fibrillation And Active Malignancy: An Analysis Of ENGAGE AF – TIMI 48 Randomized Clinical Trial

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial

Edoxaban versus warfarin in patients with atrial fibrillation in relation to stroke risk. A subanalysis of the ENGAGE AF-TIMI 48 study

Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial

Outcomes Of Asian Patients With Atrial Fibrillation Compared To Non-Asians In The ENGAGE AF-TIMI 48 Trial

The usefulness of the TIMI-AF score in the prediction of ischemic stroke and bleeding for Asian patients with atrial fibrillation

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Comparison of Events Across Definitions of Major Bleeding in the Engage AF-TIMI 48 Trial

Linking endogenous factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation- An ENGAGE AF-TIMI 48 Subanalysis

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI 48 Trial

Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials

Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis

Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial

Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation

Outcomes In 2824 Patients With Valvular Heart Disease Treated With Edoxaban Or Warfarin In The ENGAGE AF-TIMI 48 Trial

Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation

Efficacy and Safety of Oral Anticoagulation in 21105 Patients With Atrial Fibrillation Stratified by Diabetic Status in the ENGAGE AF-TIMI 48 Trial

Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48

Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy

Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF – TIMI 48 Trial: Taiwanese Perspective

Mortality in Patients With Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation Without Heart Failure in the ENGAGE AF-TIMI 48 Trial

Sudden Cardiac Death In 21,105 Patients With Atrial Fibrillation: Insights From The ENGAGE AF- TIMI 48 Trial

Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial

Edoxaban Versus Warfarin In 841 Patients With Atrial Fibrillation And Peripheral Arterial Disease: Insights From The ENGAGE AF-TIMI 48 Trial

Edoxaban Associated With Fewer Serious Adverse Events and Lower Mortality Than Warfarin, Regardless of Burden of Comorbidities: Insights From the ENGAGE AF-TIMI 48 Trial

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: a subgroup analysis from ENGAGE AF-TIMI 48 trial

Edoxaban for the Prevention of Thromboembolism in Patients With Bioprosthetic Valves in ENGAGE AF-TIMI 48

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial

Edoxaban versus Warfarin in Patients at Increased Risk of Falling – A Subgroup Analysis of the ENGAGE AF-TIMI 48 Trial

Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin- Insights From the ENGAGE AF-TIMI 48 Trial

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial

Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial

Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial

Edoxaban versus Warfarin in Patients With Atrial Fibrillation in the US FDA Approval Population: An Analysis From the ENGAGE AF-TIMI 48 Trial

Perioperative Adverse Outcomes In Patients With Atrial Fibrillation Taking Edoxaban Or Warfarin: Analysis Of The ENGAGE AF-TIMI 48 Trial

The Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial

Gastrointestinal Bleeding With Edoxaban versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial

Concomitant Use of Antiplatelet Therapy with Edoxaban or Warfarin in Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Efficacy and Safety of Edoxaban for the Management of Elderly Patients With Atrial Fibrillation: Engage AF-TIMI 48

Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Relationship Between Dose, Anti-Factor Xa Activity, And Outcomes In Patients Randomized To Edoxaban In The ENGAGE AF-TIMI 48 Trial

Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

Systemic, Non-cerebral, Arterial Embolism in 21,105 Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Results from the ENGAGE AF-TIMI 48 Trial

Edoxaban versus warfarin in patients with atrial fibrillation

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)